Last updated: February 3, 2023
Sponsor: The First Affiliated Hospital of Henan University of Science and Technology
Overall Status: Active - Not Recruiting
Phase
3
Condition
Esophageal Cancer
Squamous Cell Carcinoma
Esophageal Disorders
Treatment
N/AClinical Study ID
NCT02025036
FirstHenanUST
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- age 18-75years old
- Histologically proven squamous cell carcinoma of the esophagus the tumor was inT2-4N0-2M0
- The patients have not received the surgery or chemo-radiotherapy.
- Hb≥80g/L, absolute neutrophil count ≥1.5×109/L, Plt≥90×109/L,
- ALT、AST≤2.5N,Cr≤1.5N.
- performance status score 0-2
Exclusion
Exclusion Criteria:
- pregnant, lactating women
- Oxaliplatin or fluorouracil Allergy or metabolic disorders
- Radiotherapy contraindications
- History of organ transplantation
- Brain metastasis
- The peripheral nervous system disorders
- Severe infection
- Oral capecitabine who have difficulty with,such as dysphagia,The activities ofdigestive ulcer, Gastrointestinal bleeding
- Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,highblood pressure, diabetes.
- Other malignant tumor in recent 5 years.
Study Design
Total Participants: 249
Study Start date:
October 01, 2014
Estimated Completion Date:
April 01, 2025
Study Description
Connect with a study center
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan 471003
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.